Quinuclidine derivatives and medicinal compositions containing the same
Provided is a powder inhaler comprising a powder inhalant comprising 3(R)-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane wherein an anion X − is associated with the positive charge of the nitrogen atom and wherein X − is a pharmaceutically acceptable anion of a mono- or polyvalent acid.
1. A powder inhaler comprising a powder inhalant comprising 3(R)-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane wherein an anion X − is associated with the positive charge of the nitrogen atom and wherein X − is a pharmaceutically acceptable anion of a mono- or polyvalent acid.
2. The powder inhaler of claim 1 , wherein X − is bromide ion.
3. The powder inhaler of claim 1 , wherein the powder inhalant further comprises a pharmaceutically acceptable carrier or diluent.
4. The powder inhaler of claim 3 , wherein the pharmaceutically acceptable carrier or diluent of the powder inhalant is lactose.
5. The powder inhaler of claim 1 , wherein the powder inhalant further comprises a β 2 agonist.
6. The powder inhaler of claim 5 , wherein the powder inhalant further comprises a steroid or a phosphodiesterase IV inhibitor.
7. The powder inhaler of claim 1 , wherein the powder inhalant further comprises a steroid.
8. The powder inhaler of claim 7 , wherein the powder inhalant further comprises a phosphodiesterase IV inhibitor.
9. The powder inhaler of claim 1 , wherein the powder inhalant further comprises a phosphodiesterase IV inhibitor.
10. A method for treating chronic obstructive pulmonary disease, chronic bronchitis, bronchial hyperreactivity, asthma, or rhinitis which method comprises use of a powder inhaler of claim 1 to administer to a human patient in need of such treatment an effective amount of the powder inhalant of claim 1 .
11. The method of claim 10 further comprising administering an effective amount of a β 2 agonist.
12. The method of claim 11 further comprising administering an effective amount of a steroid or a phosphodiesterase IV inhibitor.
13. The method of claim 10 further comprising administering an effective amount of a steroid.
14. The method of claim 13 further comprising administering an effective amount of a phosphodiesterase IV inhibitor.
15. The method of claim 10 further comprising administering an effective amount of a phosphodiesterase IV inhibitor.
16. A method for inhibiting bronchospasm, which method comprises use of a powder inhaler of claim 1 to administer to a human patient in need of such treatment an effective amount of the powder inhalant of claim 1 .
17. The method of claim 16 further comprising administering an effective amount of a β 2 agonist.
18. The method of claim 17 further comprising administering an effective amount of a steroid or a phosphodiesterase IV inhibitor.
19. The method of claim 16 further comprising administering an effective amount of a steroid.
20. The method of claim 19 further comprising administering an effective amount of a phosphodiesterase IV inhibitor.
21. The method of claim 16 further comprising administering an effective amount of a phosphodiesterase IV inhibitor.